Avidity Partners Management’s Context Therapeutics CNTX Stock Holding History

Avidity Partners Management’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.77M	Hold	4,998,267	–	–	0.44%	27
2026 Q1	$13.1M	Sell	4,998,267 -506,588	-9%	-$1.18M	2.65%	8
2025 Q4	$8.09M	Sell	5,504,855 -3,477,000	-39%	-$4.06M	2.33%	11
2025 Q3	$8.7M	Buy	8,981,855 +1,504,600	+20%	+$1.22M	1.98%	14
2025 Q2	$4.9M	Buy	7,477,255 +55	+0%	+$40	0.98%	34
2025 Q1	$4.58M	Hold	7,477,200	–	–	0.87%	43
2024 Q4	$7.85M	Buy	7,477,200 +60,045	+0.8%	+$104K	0.77%	47
2024 Q3	$14.5M	Sell	7,417,155 -2,200	-0%	-$4.88K	0.74%	51
2024 Q2	$14.9M	Buy	+7,419,355	New	+$12.8M	0.63%	57

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avidity Partners Management's CNTX Position: Q2 2026 in Review

Avidity Partners Management held its Context Therapeutics (CNTX) position steady in Q2 2026 at 4,998,267 shares worth $2.77M. The position accounts for 0.44% of the portfolio, ranked #27.

Avidity Partners Management first reported a position in CNTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $14.9M in Q2 2024. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Avidity Partners Management held 4,998,267 shares of Context Therapeutics worth $2.77M as of Q2 2026.
Avidity Partners Management left its Context Therapeutics share count unchanged in Q2 2026.
Context Therapeutics made up 0.44% of Avidity Partners Management's portfolio in Q2 2026, its #27 holding.
Avidity Partners Management first reported a position in Context Therapeutics in Q2 2024 and has held it in 9 quarters since.
Avidity Partners Management's Context Therapeutics position peaked at $14.9M in Q2 2024.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.